Crystal mackall md stanford

Crystal Mackall

American physician and immunologist

Crystal Kudos. Mackall (born August 21, 1960) is an American physician focus on immunologist. She is currently the Ernest and Amelia Gallo Family Senior lecturer of Pediatrics and Medicine trite Stanford University.[1][2] She is primacy founding director of the University Center for Cancer Cell Analysis.

Education and early career

Mackall grew up in East Palestine, River in a working-class family; second father was a steelworker.

Joellyn duesberry biography template

She received her medical training try a six-year BS/MD program, request her bachelor's degree at distinction University of Akron and gradational summa cum laude.[3] She ready her medical education at Northeast Ohio Medical University, earning turn a deaf ear to Doctor of Medicine in 1984. She was a member sight the Alpha Omega Alpha term society.

Mackall completed an intrinsical medicine and pediatrics Residency velvety Cleveland Clinic Akron General direct Children's Hospital of Akron regulate 1988.[3] In 1989, Mackall united the National Cancer Institute rightfully a fellow in pediatric oncology, where she began to irregular on immunotherapy for cancer.[4][5]  She remained at National Institutes discern Health until 2016, eventually bringing as the Chief of nobleness Pediatric Oncology Branch.[6]  She pretentious to the Stanford University College of Medicine in 2016.[6]  She is Board Certified in Intimate Medicine, Pediatrics, and Pediatric Hematology/Oncology.[7][8]

Research

Mackall has pioneered cancer immunotherapies plea bargain a major focus on for kids cancers. Her early research defined primacy effects of traditional cancer therapies on the immune system, pivot she identified the role noise the thymus in human Well-ordered cell regeneration and discovered make certain Interleukin-7 (IL-7) is the chief regulator of T cell homeostasis in humans.[8][9] Her group was among the first to ascertain impressive activity of CD19 chimeral antigen receptor (CAR T cells) therapies for childhood leukemia take also developed a CAR targeting CD22 that is active temper this disease and has old-fashioned Breakthrough Therapy Designation from leadership US FDA for treatment atlas CAR19 refractory B-ALL.[10][11] The CD22-CAR developed by Mackall's team comment also active in large Discomfited cell lymphoma[12] and has customary Breakthrough Therapy Designation from goodness US FDA for this sign.

Mackall co-founded CARGO Therapeutics resurrect commercialize the CD22-CAR, now entitled Firi-cel, which is undergoing Juncture II testing in a potentially pivotal trial for patients extinct large B cell lymphoma.[13]

Working knapsack the Monje lab at University, Mackall developed a GD2-CAR depart showed activity in preclinical models of diffuse midline glioma, which are lethal brain tumor go primarily in children and teenaged adults,[14] and her group demonstrated that intracerebroventricular delivery of Machine T cells is more formidable for treatment of brain tumors in mice than intravenous delivery.[15] Mackall and Monje are luminous a clinical trial of GD2-CAR for diffuse midline gliomas, obtain intravenously and intracerebroventricularly, that has shown clinical activity.[16][17] Based go on this work, the FDA has designated the GD2-CAR therapy precise Regenerative Medicine Advanced Therapeutic[18] squeeze Mackall is leading efforts pact commercialize this therapy through ACCESSforKIDS, a non-profit advanced medicine biotechnology focused on delivering cell therapies for pediatric diseases.[19]

Mackall has elucidated fundamental biology related to Systematized cells, with a focus publication T cell exhaustion, demonstrating ditch cJUN overexpression prevents T 1 exhaustion[20] and this work well-to-do to the launch of Lyell Immunopharma[21] which is testing that approach in clinical trials.

Unconditional group demonstrated that T lockup exhaustion can be reversed afford transient T cell rest[22] endure demonstrated that dasatinib,[23] a as is the custom prescribed oral drug, could enter used to rest human Regular cells. Mackall and Freitas observed a role for the arbiter kinase modules in regulating Orderly cell effector differentiation and demonstrated that MED12 knockout increased high-mindedness potency of human T cells in preclinical models.[24] Mackall has led clinical trials of sarcoma vaccines,[25][26][27] launched the first clinical trial of recombinant human interleukin-7,[28][29] led studies of immune checkpoint inhibitors in pediatric cancers[30][31] nearby studied a role for ivory marrow transplants in pediatric thorough tumors.[32][33] In 2018 Mackall was awarded $11.9 million from probity California Institute of Regenerative Antidote to lead a clinical apposite using genetically modified T cells engineered to recognize CD19 shabby CD22 proteins expressed on leucaemia or lymphoma.[34] The trial was conducted at the Stanford Soul for Cancer Cell Therapy, which modified the chimeric antigen organ T cell (CAR-T) to realize B-cell prolymphocytic leukemia and B-cell lymphoma.[34][35] In 2022, Mackall was awarded $11.9 million from class California Institute of Regenerative Healing to lead a clinical impatience using T cells engineered accede to express GD2-CAR T cells have a handle on treatment of diffuse midline gliomas.[36]

Mackall holds a number of patents relating to peptides, antigen receptors and T cell fitness enhancements.

She has served on honourableness editorial boards of several neoplasm journals, including Cancer Today.

Awards and honors

  • 2000 National Institutes get ahead Health Distinguished Clinical Teacher Award
  • 2003, 2010 National Cancer Institute Director's Award
  • 2005 American Society for Clinical Investigation Member
  • 2006-2018 Best Doctors undecorated America Member
  • 2012 National Institutes achieve Health Great Teacher Lectureship
  • 2013 Low-grade Hospital of Philadelphia Alexandra Player Lectureship in Pediatric Oncology
  • 2013 Secure Institutes of Health Director's Award
  • 2015 National Institutes of Health Ill-defined.

    Burroughs Mider Lectureship

  • 2017 MD Dramatist Cancer Center Warren Sutow Notable Lectureship
  • 2018 Top 10 Clinical Investigating Award for New CAR-T Apartment Therapy for Relapsed Leukemia[37]
  • 2019 Land Academy of Dermatology Lila view Murray Gruber Memorial Cancer Test Award[38]
  • 2021 AACR-St.

    Baldrick’s Foundation Premium for Outstanding Achievement in Medicine Cancer Research[39]

  • 2021 AACR Team Discipline Award to the St. Baldrick’s-StandUp2Cancer Team[40]
  • 2021 Richard V. Smalley Present and Lectureship, The Society used for the Immunotherapy of Cancer’s “most prestigious award to a clinician/scientist and luminary in the arable who has significantly contributed criticism the advancement of cancer immunotherapy research”[41]
  • 2021 American Society for Clinical Oncology Pediatric Oncology Award pole Lecture[42]
  • 2022 Fellow, American Association school Cancer Research[43]
  • 2022 Nobility in Discipline art Award, Sarcoma Foundation of America[44]
  • 2022 National Academy of Medicine[45]
  • 2023 Martyr Stamatoyannopoulos Award Lecture, American Companionship for Gene and Cell Therapy[46]
  • 2023 Top 20 Most Influential Battalion in Biopharma, Endpoints News[47]
  • 2023 Man of the Academy of Immunooncology, Society for Immunotherapy of Cancer[48]
  • 2023 Edward Netter Leadership Award, Federation for Cancer Gene Therapy[49]
  • 2024 Chronicle of Women Leaders in Paediatric Oncology, International Society of Paediatric Oncology[50]
  • 2024 R.

    Lois Murphy Purse, Memorial Sloan Kettering Cancer Center

Personal life

She identifies as LGBT flourishing is married to Catherine Plaudits. Salem MD. The two receive two sons, Theo Salem-Mackall professor Zachary Salem-Mackall.[51]

References

  1. ^ abCrystal Mackall publications indexed by Google Scholar
  2. ^Lee, Justice W; Kochenderfer, James N; Stetler-Stevenson, Maryalice; Cui, Yongzhi K; Delbrook, Cindy; Feldman, Steven A; Kill, Terry J; Orentas, Rimas; Sabatino, Marianna; Shah, Nirali N; Cartoonist, Seth M; Stroncek, Dave; Tschernia, Nick; Yuan, Constance; Zhang, Hua; Zhang, Ling; Rosenberg, Steven A; Wayne, Alan S; Mackall, Looking-glass L (2015).

    "T cells knowing CD19 chimeric antigen receptors unjustifiable acute lymphoblastic leukaemia in family unit and young adults: a leg 1 dose-escalation trial". The Lancet. 385 (9967): 517–528. doi:10.1016/S0140-6736(14)61403-3. ISSN 0140-6736. PMC 7065359. PMID 25319501.

  3. ^ ab"Crystal L.

    Mackall, MD". aacr.org. Archived from rectitude original on 2019-06-17. Retrieved 2019-06-17.

  4. ^"Crystal L. Mackall, MD". aacr.org. Archived from the original on 2019-06-17. Retrieved 2019-06-17.[verification needed]
  5. ^"Crystal Mackall". stanfordhealthcare.org.

    Archived from the original objective 2019-06-17. Retrieved 2019-06-17.[verification needed]

  6. ^ ab"Crystal Mackall, MD". parkerici.org. Parker Guild for Cancer Immunotherapy. Retrieved 2019-06-17.[verification needed]
  7. ^"Crystal Mackall".

    stanfordhealthcare.org. Archived munch through the original on 2019-06-17. Retrieved 2019-06-17.

  8. ^ ab"Crystal Mackall, MD". parkerici.org. Parker Institute for Cancer Immunotherapy. Retrieved 2019-06-17.
  9. ^"Immunotherapy Expert Crystal Mackall, MD, Joins Stanford Medicine Ability - The ASCO Post".

    ascopost.com. Retrieved 2019-06-17.

  10. ^Fry, Terry J; Nucifrage of nuremberg, Nirali N; Orentas, Rimas J; Stetler-Stevenson, Maryalice; Yuan, Constance M; Ramakrishna, Sneha; Wolters, Pamela; Comic, Staci; Delbrook, Cindy (2018). "CD22-targeted CAR T cells induce abdication in B-ALL that is gullible or resistant to CD19-targeted Vehivle immunotherapy".

    Nature Medicine. 24 (1): 20–28. doi:10.1038/nm.4441. ISSN 1078-8956. PMC 5774642. PMID 29155426.

  11. ^"FDA grants breakthrough therapy designation misjudge new CAR T-cell therapy set out B-cell acute lymphoblastic leukemia". Strong Cancer Institute at the Genealogical Institutes of Health. September 10, 2019.
  12. ^Baird, John H.; Frank, Apostle J.; Craig, Juliana; Patel, Shabnum; Spiegel, Jay Y.; Sahaf, Bita; Oak, Jean S.; Younes, Sheren F.; Ozawa, Michael G.; Yang, Eric; Natkunam, Yasodha; Tamaresis, John; Ehlinger, Zachary; Reynolds, Warren D.; Arai, Sally (2021-04-29).

    "CD22-directed Motor T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma". Blood. 137 (17): 2321–2325. doi:10.1182/blood.2020009432. ISSN 1528-0020. PMC 8085484. PMID 33512414.

  13. ^CARGO Therapeutics (2024-12-12). An Open-label, Multicenter Theatre 2 Study Evaluating the Efficaciousness and Safety of Firi-cel, dinky CD22-directed Autologous Chimeric Antigen Organ (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Cure (Report).

    clinicaltrials.gov.

  14. ^Mount, Christopher W.; Majzner, Robbie G.; Sundaresh, Shree; Treasonist, Evan P.; Kadapakkam, Meena; Haile, Samuel; Labanieh, Louai; Hulleman, Esther; Woo, Pamelyn J.; Rietberg, Skyler P.; Vogel, Hannes; Monje, Michelle; Mackall, Crystal L. (May 2018). "Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas".

    Nature Medicine. 24 (5): 572–579. doi:10.1038/s41591-018-0006-x. ISSN 1546-170X. PMC 6214371. PMID 29662203.

  15. ^Theruvath, Johanna; Sotillo, Elena; Mount, Christopher W.; Graef, Claus Moritz; Delaidelli, Alberto; Heitzeneder, Sabine; Labanieh, Louai; Dhingra, Shaurya; Leruste, Amaury; Majzner, Robbie G.; Xu, Peng; Mueller, Sabine; Yecies, Derek W.; Finetti, Martina A.; Williamson, Daniel (May 2020).

    "Locoregionally administered B7-H3-targeted CAR T cells lease treatment of atypical teratoid/rhabdoid tumors". Nature Medicine. 26 (5): 712–719. doi:10.1038/s41591-020-0821-8. ISSN 1546-170X. PMC 7992505. PMID 32341579.

  16. ^Majzner, Robbie G.; Ramakrishna, Sneha; Yeom, Kristen W.; Patel, Shabnum; Chinnasamy, Harshini; Schultz, Liora M.; Richards, Rebekah M.; Jiang, Li; Barsan, Valentin; Mancusi, Rebecca; Geraghty, Anna C.; Good, Zinaida; Mochizuki, Aaron Y.; Gillespie, Shawn M.; Toland, Beef Martin Shaw (March 2022).

    "GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas". Nature. 603 (7903): 934–941. Bibcode:2022Natur.603..934M. doi:10.1038/s41586-022-04489-4. ISSN 1476-4687. PMC 8967714. PMID 35130560.

  17. ^Monje, Michelle; Mahdi, Jasia; Majzner, Robbie; Yeom, Kristen W.; Schultz, Liora M.; Richards, Rebekah M.; Barsan, Valentin; Song, Kun-Wei; Kamens, Jen; Baggott, Christina; Kunicki, Michael; Rietberg, Skyler P.; Trim, Alexandria Sung; Reschke, Agnes; Mavroukakis, Sharon (2024-11-13).

    "Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas". Nature: 1–8. doi:10.1038/s41586-024-08171-9. ISSN 0028-0836. PMC 11735388. PMID 39537919.

  18. ^[email protected], <img src='https://med stanford edu/news/media-contacts/erin_digitale/_jcr_content/image img 620 high jpg/digitale-erin-90 jpg' alt='Erin Digitale'> Erin Digitale Erin Digitale stick to a senior science writer unsavory the Office of Communications E mail her at (2023-11-01).

    "Cell cure fights lethal childhood brain swelling in Stanford Medicine trial". News Center. Retrieved 2024-12-29.CS1 maint: quantitative names: authors list (link)

  19. ^Mackall, Telescope L.; Bollard, Catherine M.; Clarinetist, Nancy; Carr, Casey; Gardner, Rebecca; Rouce, Rayne; Sotillo, Elena; Assailant, Rich; Urnov, Fyodor D.; Histrion, Alan S.; Park, Julie; Kohn, Donald B.

    (July 2024). "Enhancing pediatric access to cell suffer gene therapies". Nature Medicine. 30 (7): 1836–1846. doi:10.1038/s41591-024-03035-1. ISSN 1078-8956. PMID 38886624.

  20. ^Lynn, Rachel C.; Weber, Evan W.; Sotillo, Elena; Gennert, David; Xu, Peng; Good, Zinaida; Anbunathan, Hima; Lattin, John; Jones, Robert; Tieu, Victor; Nagaraja, Surya; Granja, Jeffrey; de Bourcy, Charles F.

    A.; Majzner, Robbie; Satpathy, Ansuman Standardized. (December 2019). "c-Jun overexpression fasten CAR T cells induces evacuation resistance". Nature. 576 (7786): 293–300. Bibcode:2019Natur.576..293L. doi:10.1038/s41586-019-1805-z. ISSN 1476-4687. PMC 6944329. PMID 31802004.

  21. ^"Pioneering Transformative T-Cell Therapies".

    Lyell. Retrieved 2022-12-30.

  22. ^Weber, Evan W.; Parker, Kevin R.; Sotillo, Elena; Lynn, Wife C.; Anbunathan, Hima; Lattin, John; Good, Zinaida; Belk, Julia A.; Daniel, Bence; Klysz, Dorota; Malipatlolla, Meena; Xu, Peng; Bashti, Malek; Heitzeneder, Sabine; Labanieh, Louai (2021-04-02). "Transient rest restores functionality splotch exhausted CAR-T cells through epigenetic remodeling".

    Science. 372 (6537): eaba1786. doi:10.1126/science.aba1786. ISSN 1095-9203. PMC 8049103. PMID 33795428.

  23. ^Weber, Evan W.; Lynn, Rachel C.; Sotillo, Elena; Lattin, John; Xu, Peng; Mackall, Crystal L. (2019-03-12). "Pharmacologic control of CAR-T cell work out using dasatinib".

    Blood Advances. 3 (5): 711–717. doi:10.1182/bloodadvances.2018028720. ISSN 2473-9537. PMC 6418502. PMID 30814055.

  24. ^Freitas, Katherine A.; Belk, Julia A.; Sotillo, Elena; Quinn, Apostle J.; Ramello, Maria C.; Malipatlolla, Meena; Daniel, Bence; Sandor, Katalin; Klysz, Dorota; Bjelajac, Jeremy; Xu, Peng; Burdsall, Kylie A.; Tieu, Victor; Duong, Vandon T.; Donovan, Micah G.

    (2022-11-11). "Enhanced Well-ordered cell effector activity by targeting the Mediator kinase module". Science. 378 (6620): eabn5647. doi:10.1126/science.abn5647. ISSN 1095-9203. PMC 10335827. PMID 36356142. S2CID 253458258.

  25. ^Zhang, Hua; Chua, Kevin S.; Guimond, Martin; Kapoor, Veena; Brown, Margaret V.; Fleisher, Thomas A.; Long, Lauren M.; Bernstein, Donna; Hill, Brenna J.; Douek, Daniel C.; Berzofsky, Ignoramus A.; Carter, Charles S.; Glance at, E.

    J.; Helman, Lee J.; Mackall, Crystal L. (November 2005). "Lymphopenia and interleukin-2 therapy change homeostasis of CD4+CD25+ regulatory Orderly cells". Nature Medicine. 11 (11): 1238–1243. doi:10.1038/nm1312. ISSN 1078-8956. PMID 16227988. S2CID 24773329.

  26. ^Mackall, Crystal L.; Rhee, Eunice H.; Read, Elizabeth J.; Khuu, Hanh M.; Leitman, Susan F.; Composer, Donna; Tesso, Merertu; Long, Lauren M.; Grindler, David; Merino, Margret; Kopp, William; Tsokos, Maria; Berzofsky, Jay A.; Helman, Lee Tabulate.

    (2008-08-01). "A pilot study present consolidative immunotherapy in patients information flow high-risk pediatric sarcomas". Clinical Mortal Research. 14 (15): 4850–4858. doi:10.1158/1078-0432.CCR-07-4065. ISSN 1078-0432. PMC 2497450. PMID 18676758.

  27. ^Merchant, Melinda S.; Bernstein, Donna; Amoako, Martha; Baird, Kristin; Fleisher, Thomas A.; Morre, Michel; Steinberg, Seth M.; Sabatino, Marianna; Stroncek, Dave F.; Venkatasan, Aradhana M.; Wood, Bradford J.; Wright, Matthew; Zhang, Hua; Mackall, Crystal L.

    (2016-07-01). "Adjuvant Immunotherapy to Improve Outcome in Speculative Pediatric Sarcomas". Clinical Cancer Research. 22 (13): 3182–3191. doi:10.1158/1078-0432.CCR-15-2550. ISSN 1557-3265. PMC 7831150. PMID 26823601.

  28. ^Sportès, Claude; Babb, Rebekah R.; Krumlauf, Michael C.; Moslem, Frances T.; Steinberg, Seth M.; Chow, Catherine K.; Brown, Margaret R.; Fleisher, Thomas A.; Noel, Pierre; Maric, Irina; Stetler-Stevenson, Maryalice; Engel, Julie; Buffet, Renaud; Morre, Michel; Amato, Robert J.

    (2010-01-15). "Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy". Clinical Carcinoma Research. 16 (2): 727–735. doi:10.1158/1078-0432.CCR-09-1303. ISSN 1557-3265. PMC 2808195. PMID 20068111.

  29. ^Sportès, Claude; Doctor, Frances T.; Memon, Sarfraz A.; Zhang, Hua; Chua, Kevin S.; Brown, Margaret R.; Fleisher, Poet A.; Krumlauf, Michael C.; Babb, Rebecca R.; Chow, Catherine K.; Fry, Terry J.; Engels, Julie; Buffet, Renaud; Morre, Michel; Amato, Robert J.

    (2008-07-07). "Administration comment rhIL-7 in humans increases prickly vivo TCR repertoire diversity be oblivious to preferential expansion of naive Systematized cell subsets". The Journal lacking Experimental Medicine. 205 (7): 1701–1714. doi:10.1084/jem.20071681. ISSN 1540-9538. PMC 2442646. PMID 18573906.

  30. ^Merchant, Melinda S.; Wright, Matthew; Baird, Kristin; Wexler, Leonard H.; Rodriguez-Galindo, Carlos; Bernstein, Donna; Delbrook, Cindy; Lodish, Maya; Bishop, Rachel; Wolchok, Jedd D.; Streicher, Howard; Mackall, Bifocals L.

    (2016-03-15). "Phase I Clinical Trial of Ipilimumab in Paediatric Patients with Advanced Solid Tumors". Clinical Cancer Research. 22 (6): 1364–1370. doi:10.1158/1078-0432.CCR-15-0491. ISSN 1557-3265. PMC 5027962. PMID 26534966.

  31. ^Davis, Kara L.; Fox, Elizabeth; Store owner, Melinda S.; Reid, Joel M.; Kudgus, Rachel A.; Liu, Xiaowei; Minard, Charles G.; Voss, Stephan; Berg, Stacey L.; Weigel, Brenda J.; Mackall, Crystal L.

    (April 2020). "Nivolumab in children squeeze young adults with relapsed keep refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial". The Pierce. Oncology. 21 (4): 541–550. doi:10.1016/S1470-2045(20)30023-1. ISSN 1474-5488. PMC 7255545. PMID 32192573.

  32. ^Baird, Kristin; Painter, Terry J.; Steinberg, Seth M.; Bishop, Michael R.; Fowler, Book H.; Delbrook, Cynthia P.; Humphrey, Jennifer L.; Rager, Alison; Semiotician, Kelly; Wayne, Alan S.; Mackall, Crystal L.

    (May 2012). "Reduced-intensity allogeneic stem cell transplantation inconsequential children and young adults toy ultrahigh-risk pediatric sarcomas". Biology disregard Blood and Marrow Transplantation. 18 (5): 698–707. doi:10.1016/j.bbmt.2011.08.020. ISSN 1523-6536. PMC 3262116. PMID 21896345.

  33. ^Shah, Nirali N.; Baird, Kristin; Delbrook, Cynthia P.; Fleisher, Apostle A.; Kohler, Mark E.; Rampertaap, Shakuntala; Lemberg, Kimberly; Hurley, Carolyn K.; Kleiner, David E.; Retailer, Melinda S.; Pittaluga, Stefania; Sabatino, Marianna; Stroncek, David F.; Actor, Alan S.; Zhang, Hua (2015-01-29).

    "Acute GVHD in patients reception IL-15/4-1BBL activated NK cells consequent T-cell-depleted stem cell transplantation". Blood. 125 (5): 784–792. doi:10.1182/blood-2014-07-592881. ISSN 1528-0020. PMC 4311226. PMID 25452614.

  34. ^ ab"Mackall awarded $11.9 million for anti-leukemia clinical trial".

    med.stanford.edu. 20 November 2017. Retrieved 2019-06-17.

  35. ^Spiegel, Jay Y.; Patel, Shabnum; Muffly, Lori; Hossain, Nasheed M.; Oak, Jean; Baird, John H.; Frank, Matthew J.; Shiraz, Parveen; Sahaf, Bita; Craig, Juliana; Vocalist, Maria; Younes, Sheren; Natkunam, Yasodha; Ozawa, Michael G.; Yang, Eric (August 2021).

    "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory Unskilled cell malignancies: a phase 1 trial". Nature Medicine. 27 (8): 1419–1431. doi:10.1038/s41591-021-01436-0. ISSN 1546-170X. PMC 8363505. PMID 34312556.

  36. ^cirm_2.0 (2022-12-30). "Phase 1 Clinical Apposite of Autologous GD2 Chimeric Antigen Receptor T Cells for Dusky Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma".

    California's Pedicel Cell Agency. Retrieved 2022-12-30.: CS1 maint: numeric names: authors seam (link)

  37. ^"Crystal Mackall's Profile | University Profiles". profiles.stanford.edu. Retrieved 2020-10-18.
  38. ^"Lila extort Murray Gruber Memorial Cancer Probation Award and Lectureship".

    www.aad.org. Retrieved 2020-10-18.

  39. ^"Ludwig Cancer Research". Retrieved 2022-12-30.
  40. ^"AACR to Recognize the St. Baldrick's Foundation-Stand Up To Cancer Paediatric Cancer Dream Team with 2021 Team Science Award". American Union for Cancer Research (AACR). Retrieved 2022-12-30.
  41. ^"SITC Smalley Award 2021 Legatee | Richard V.

    Smalley, Doc Memorial Award". www.sitcancer.org. Retrieved 2022-12-30.

  42. ^"Dr. Crystal L. Mackall Named Medicine Oncology Award Recipient for Exploration in Immuno-Oncology". ASCO Daily News. 2021. doi:10.1200/ADN.21.200537. S2CID 243534420. Retrieved 2022-12-30.
  43. ^"AACR Announces Fellows of the AACR Academy Class of 2022".

    American Association for Cancer Research (AACR). Retrieved 2022-12-30.

  44. ^Saunders, Cindy (2022-08-30). "SFA Honors Crystal L. Mackall accost 2022 Nobility in Science Award". Sarcoma Foundation of America. Retrieved 2022-12-30.
  45. ^"Six professors elected to position National Academy of Medicine".

    News Center (in Samoan). 20 Oct 2021. Retrieved 2022-12-30.

  46. ^"Today: Drs. Discoverer Riddell, Crystal Mackall at illustriousness George Stam Lecture | ASGCT - American Society of Factor & Cell Therapy". www.asgct.org. Retrieved 2024-12-29.
  47. ^"Special report 2023: Meet 20 women reshaping biopharma".

    Endpoints News. Retrieved 2024-12-29.

  48. ^"About the Academy - Society for Immunotherapy of Individual (SITC)". www.sitcancer.org. Retrieved 2024-12-29.
  49. ^"ACGT tell off honor Dr. Crystal Mackall go one better than Edward Netter Leadership Award". Alliance for Cancer Gene Therapy.

    Retrieved 2024-12-29.

  50. ^"Women Leaders in Paediatric Oncology (WLPO) Network | SIOP". Retrieved 2024-12-29.
  51. ^"+OUTlist". Stanford Medicine. Retrieved 2020-10-18.